Essential Updates 2024–2026: Advances in Colorectal Cancer Surgery

ABSTRACT

Surgical innovation in colorectal cancer is increasingly judged not by technical feasibility alone, but by whether it improves oncological outcomes, preserves function, reduces morbidity, or makes difficult procedures more reproducible. This structured narrative review examines major surgical studies published from January 2024 through July 2026, while retaining earlier landmark reports when needed to interpret safety and implementation. The strongest recent randomized evidence concerns robot‐assisted rectal cancer surgery. In the REAL trial, robotic surgery improved 3‐year locoregional control, disease‐free survival, and early functional recovery compared with laparoscopy in middle and low rectal cancer, although overall survival did not differ and generalizability beyond experienced Chinese centers remains uncertain. For transanal total mesorectal excision, noninferiority in the TaLaR trial must be interpreted in light of its −10% margin, the experience of participating centers, and early reports of multifocal local recurrence during implementation. Individual trials of indocyanine green fluorescence angiography have yielded mixed results; however, a 2026 meta‐analysis of nine randomized trials found lower leakage rates overall and after left‐sided and rectal resections, but not after right‐sided colectomy, supporting procedure‐specific use. Robotic colectomy is feasible but has not clearly surpassed mature laparoscopy. Intracorporeal anastomosis is associated with faster recovery and greater flexibility in extraction‐site selection and may reduce extraction‐site hernia, whereas long‐term oncological equivalence has not yet been established. Across these fields, benefit appears context‐specific and closely linked to case selection, surgeon experience, technical standardization, and structured audit.